JP2018521999A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521999A5 JP2018521999A5 JP2017568205A JP2017568205A JP2018521999A5 JP 2018521999 A5 JP2018521999 A5 JP 2018521999A5 JP 2017568205 A JP2017568205 A JP 2017568205A JP 2017568205 A JP2017568205 A JP 2017568205A JP 2018521999 A5 JP2018521999 A5 JP 2018521999A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- fusion protein
- hvem
- mutation
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102220031963 rs431825178 Human genes 0.000 claims description 113
- 102220475086 Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6_L90A_mutation Human genes 0.000 claims description 93
- 108020001507 fusion proteins Proteins 0.000 claims description 67
- 102000037865 fusion proteins Human genes 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 59
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 56
- 102000012220 Member 14 Tumor Necrosis Factor Receptors Human genes 0.000 claims description 56
- 102200112077 rs747956857 Human genes 0.000 claims description 54
- 102000004169 proteins and genes Human genes 0.000 claims description 53
- 108090000623 proteins and genes Proteins 0.000 claims description 53
- 230000035772 mutation Effects 0.000 claims description 45
- 102220571043 Protein CFAP210_L70E_mutation Human genes 0.000 claims description 31
- 102220506859 Small proline-rich protein 3_L70N_mutation Human genes 0.000 claims description 31
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 22
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 22
- 230000026731 phosphorylation Effects 0.000 claims description 17
- 238000006366 phosphorylation reaction Methods 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- -1 or CXCL-8 Proteins 0.000 claims description 12
- 230000011664 signaling Effects 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 11
- 229960004641 rituximab Drugs 0.000 claims description 9
- 102220090537 rs876657931 Human genes 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 229940122494 BTLA agonist Drugs 0.000 claims description 7
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 claims description 6
- 102000019149 MAP kinase activity proteins Human genes 0.000 claims description 6
- 108040008097 MAP kinase activity proteins Proteins 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 claims description 6
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims description 6
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 229960000548 alemtuzumab Drugs 0.000 claims description 5
- 229960005027 natalizumab Drugs 0.000 claims description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 102100037354 Ectodysplasin-A Human genes 0.000 claims description 4
- 101000880080 Homo sapiens Ectodysplasin-A Proteins 0.000 claims description 4
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims description 4
- 108010005716 Interferon beta-1a Proteins 0.000 claims description 4
- 102100033461 Interleukin-17A Human genes 0.000 claims description 4
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 4
- 229960002964 adalimumab Drugs 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 229960000556 fingolimod Drugs 0.000 claims description 4
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 4
- 229940048921 humira Drugs 0.000 claims description 4
- 229960000598 infliximab Drugs 0.000 claims description 4
- 229940116176 remicade Drugs 0.000 claims description 4
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 claims description 4
- 229960003989 tocilizumab Drugs 0.000 claims description 4
- 229960005267 tositumomab Drugs 0.000 claims description 4
- 229940079023 tysabri Drugs 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 102000000704 Interleukin-7 Human genes 0.000 claims description 3
- 108010002586 Interleukin-7 Proteins 0.000 claims description 3
- 102000000585 Interleukin-9 Human genes 0.000 claims description 3
- 108010002335 Interleukin-9 Proteins 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 229960003115 certolizumab pegol Drugs 0.000 claims description 3
- ZMEWRPBAQVSBBB-GOTSBHOMSA-N (2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[[2-[2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetyl]amino]hexanoic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 ZMEWRPBAQVSBBB-GOTSBHOMSA-N 0.000 claims description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 2
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims description 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 102100026882 Alpha-synuclein Human genes 0.000 claims description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 2
- 108010046080 CD27 Ligand Proteins 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 108010029697 CD40 Ligand Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102100032937 CD40 ligand Human genes 0.000 claims description 2
- 108010065524 CD52 Antigen Proteins 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000014311 Cushing syndrome Diseases 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 108010092160 Dactinomycin Proteins 0.000 claims description 2
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 claims description 2
- 102100023688 Eotaxin Human genes 0.000 claims description 2
- 108010008165 Etanercept Proteins 0.000 claims description 2
- 101150064015 FAS gene Proteins 0.000 claims description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 claims description 2
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 claims description 2
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 2
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims description 2
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims description 2
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 claims description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 2
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 claims description 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims description 2
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 claims description 2
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 claims description 2
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims description 2
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 101000679921 Homo sapiens Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 claims description 2
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 claims description 2
- 101000679907 Homo sapiens Tumor necrosis factor receptor superfamily member 27 Proteins 0.000 claims description 2
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 101000920026 Homo sapiens Tumor necrosis factor receptor superfamily member EDAR Proteins 0.000 claims description 2
- 108010005714 Interferon beta-1b Proteins 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 claims description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 2
- 108090000174 Interleukin-10 Proteins 0.000 claims description 2
- 102000003814 Interleukin-10 Human genes 0.000 claims description 2
- 108090000177 Interleukin-11 Proteins 0.000 claims description 2
- 102000003815 Interleukin-11 Human genes 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 102000003816 Interleukin-13 Human genes 0.000 claims description 2
- 108090000176 Interleukin-13 Proteins 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 102000003812 Interleukin-15 Human genes 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102100039064 Interleukin-3 Human genes 0.000 claims description 2
- 102000004388 Interleukin-4 Human genes 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 102000000743 Interleukin-5 Human genes 0.000 claims description 2
- 108010002616 Interleukin-5 Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 101100046559 Mus musculus Tnfrsf12a gene Proteins 0.000 claims description 2
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 102000014128 RANK Ligand Human genes 0.000 claims description 2
- 108010025832 RANK Ligand Proteins 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims description 2
- 101150056647 TNFRSF4 gene Proteins 0.000 claims description 2
- 108700012411 TNFSF10 Proteins 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 2
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 claims description 2
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 claims description 2
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims description 2
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 claims description 2
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims description 2
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 2
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims description 2
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims description 2
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims description 2
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 claims description 2
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 claims description 2
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims description 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 2
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 2
- 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 claims description 2
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 claims description 2
- 102100022202 Tumor necrosis factor receptor superfamily member 27 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 102100030810 Tumor necrosis factor receptor superfamily member EDAR Human genes 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims description 2
- 229960003697 abatacept Drugs 0.000 claims description 2
- 229960000446 abciximab Drugs 0.000 claims description 2
- 210000001015 abdomen Anatomy 0.000 claims description 2
- 229940119059 actemra Drugs 0.000 claims description 2
- 229930183665 actinomycin Natural products 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 229940057415 aubagio Drugs 0.000 claims description 2
- 229940120638 avastin Drugs 0.000 claims description 2
- 229940003504 avonex Drugs 0.000 claims description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002170 azathioprine Drugs 0.000 claims description 2
- 229960004669 basiliximab Drugs 0.000 claims description 2
- 229940021459 betaseron Drugs 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 2
- 229960001467 bortezomib Drugs 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 229940112129 campath Drugs 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- 210000000038 chest Anatomy 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004630 chlorambucil Drugs 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 229940090100 cimzia Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 229940038717 copaxone Drugs 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229960000684 cytarabine Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- 210000002249 digestive system Anatomy 0.000 claims description 2
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 claims description 2
- 229950005454 doxifluridine Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002066 eicosanoids Chemical class 0.000 claims description 2
- 229940073621 enbrel Drugs 0.000 claims description 2
- 210000003372 endocrine gland Anatomy 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 229960000578 gemtuzumab Drugs 0.000 claims description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 229940022353 herceptin Drugs 0.000 claims description 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims description 2
- 229940054136 kineret Drugs 0.000 claims description 2
- 229940047834 lemtrada Drugs 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 210000004324 lymphatic system Anatomy 0.000 claims description 2
- 229950008001 matuzumab Drugs 0.000 claims description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 2
- 229960004961 mechlorethamine Drugs 0.000 claims description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 2
- 229960001428 mercaptopurine Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 229940035567 orencia Drugs 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 229960000402 palivizumab Drugs 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 108010027737 peginterferon beta-1a Proteins 0.000 claims description 2
- 210000004197 pelvis Anatomy 0.000 claims description 2
- 229960005079 pemetrexed Drugs 0.000 claims description 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 2
- 229950011098 pendetide Drugs 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 210000004303 peritoneum Anatomy 0.000 claims description 2
- 229940007060 plegridy Drugs 0.000 claims description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 229940038850 rebif Drugs 0.000 claims description 2
- 229940107685 reopro Drugs 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 229940068638 simponi Drugs 0.000 claims description 2
- 229940115586 simulect Drugs 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 229940036185 synagis Drugs 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229940121136 tecfidera Drugs 0.000 claims description 2
- 229950008860 technetium (99mtc) fanolesomab Drugs 0.000 claims description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 2
- 229960001278 teniposide Drugs 0.000 claims description 2
- 229960000331 teriflunomide Drugs 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 210000001541 thymus gland Anatomy 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 229960003087 tioguanine Drugs 0.000 claims description 2
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- 229960004355 vindesine Drugs 0.000 claims description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 2
- 229940099073 xolair Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 102000026633 IL6 Human genes 0.000 claims 1
- 108091058560 IL8 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 229960000284 efalizumab Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 229930013356 epothilone Natural products 0.000 claims 1
- 150000003883 epothilone derivatives Chemical class 0.000 claims 1
- 229940082789 erbitux Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229960000470 omalizumab Drugs 0.000 claims 1
- 230000000849 parathyroid Effects 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100026688 Interferon epsilon Human genes 0.000 description 1
- 101710147309 Interferon epsilon Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021083133A JP2021113240A (ja) | 2015-06-30 | 2021-05-17 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
| JP2022115473A JP7559013B2 (ja) | 2015-06-30 | 2022-07-20 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
| JP2023210069A JP2024019529A (ja) | 2015-06-30 | 2023-12-13 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187105P | 2015-06-30 | 2015-06-30 | |
| US62/187,105 | 2015-06-30 | ||
| PCT/US2016/040108 WO2017004213A1 (en) | 2015-06-30 | 2016-06-29 | Btla fusion protein agonists and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021083133A Division JP2021113240A (ja) | 2015-06-30 | 2021-05-17 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521999A JP2018521999A (ja) | 2018-08-09 |
| JP2018521999A5 true JP2018521999A5 (enExample) | 2019-06-06 |
| JP7116285B2 JP7116285B2 (ja) | 2022-08-10 |
Family
ID=57609132
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568205A Active JP7116285B2 (ja) | 2015-06-30 | 2016-06-29 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
| JP2021083133A Pending JP2021113240A (ja) | 2015-06-30 | 2021-05-17 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
| JP2022115473A Active JP7559013B2 (ja) | 2015-06-30 | 2022-07-20 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
| JP2023210069A Pending JP2024019529A (ja) | 2015-06-30 | 2023-12-13 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021083133A Pending JP2021113240A (ja) | 2015-06-30 | 2021-05-17 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
| JP2022115473A Active JP7559013B2 (ja) | 2015-06-30 | 2022-07-20 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
| JP2023210069A Pending JP2024019529A (ja) | 2015-06-30 | 2023-12-13 | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10961297B2 (enExample) |
| EP (1) | EP3317297A4 (enExample) |
| JP (4) | JP7116285B2 (enExample) |
| KR (2) | KR20240110000A (enExample) |
| CN (2) | CN114853903A (enExample) |
| AU (3) | AU2016286108B2 (enExample) |
| BR (1) | BR112017028316A2 (enExample) |
| CA (1) | CA2990885A1 (enExample) |
| EA (1) | EA201890171A1 (enExample) |
| IL (2) | IL256383B2 (enExample) |
| MX (1) | MX2018000073A (enExample) |
| SG (1) | SG10201913567QA (enExample) |
| WO (1) | WO2017004213A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10689449B2 (en) | 2015-01-20 | 2020-06-23 | Igm Biosciences, Inc. | Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof |
| KR20240110000A (ko) | 2015-06-30 | 2024-07-12 | 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 | Btla 융합 단백질 작용제 및 이의 용도 |
| GB201820554D0 (en) | 2018-12-17 | 2019-01-30 | Univ Oxford Innovation Ltd | BTLA antibodies |
| GB202008860D0 (en) | 2020-06-11 | 2020-07-29 | Univ Oxford Innovation Ltd | BTLA antibodies |
| WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291207B1 (en) * | 1995-07-28 | 2001-09-18 | Northwestern University | Herpes virus entry receptor protein |
| TR200504220T2 (tr) | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. |
| US8546541B2 (en) | 2002-06-20 | 2013-10-01 | Washington University | Compositions and methods for modulating lymphocyte activity |
| AU2003243781A1 (en) | 2002-06-24 | 2004-01-06 | Amniotech, Inc. | Amniotic membrane mediated delivery of bioactive molecules |
| EP1560593B1 (en) | 2002-10-25 | 2016-04-20 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| EP1812465B1 (en) * | 2004-11-12 | 2016-09-07 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| US8188232B1 (en) | 2004-11-15 | 2012-05-29 | Washington University In St. Louis | Compositions and methods for modulating lymphocyte activity |
| US8349320B2 (en) * | 2004-12-09 | 2013-01-08 | La Jolla Institute For Allergy And Immunology | Compositions and methods for modulating responses mediated or associated with BTLA activity |
| WO2010006071A1 (en) | 2008-07-08 | 2010-01-14 | La Jolla Institute For Allergy And Immunology | Hvem/btla, hvem/cd160 and hvem/gd cis complexes and methods of use |
| WO2006063067A2 (en) * | 2004-12-09 | 2006-06-15 | La Jolla Institute For Allergy And Immunology | Novel tnf receptor regulatory domain |
| WO2007010692A1 (ja) | 2005-07-19 | 2007-01-25 | Japan Science And Technology Agency | Ｈｖｅｍ及びｂｔｌａを標的とした炎症性腸疾患治療用医薬組成物及び治療方法 |
| CA2669921A1 (en) | 2006-11-15 | 2008-06-26 | Medarex, Inc. | Human monoclonal antibodies to btla and methods of use |
| US8318662B2 (en) | 2009-03-16 | 2012-11-27 | Korea Institute Of Radiological & Medical Sciences | Protein increasing cell infectivity of herpes simplex virus and use thereof |
| US8303952B2 (en) | 2009-06-08 | 2012-11-06 | Washington University | Methods for inducing in vivo tolerance |
| EP2459594A1 (en) | 2009-07-31 | 2012-06-06 | N.V. Organon | Fully human antibodies to btla |
| US9982023B2 (en) * | 2011-11-15 | 2018-05-29 | Sanford-Burnham Medical Research Institute | Compositions and methods for treating autoimmune and inflammatory disorders |
| US10759863B2 (en) | 2013-09-05 | 2020-09-01 | Sanford Burnham Prebys Medical Discovery Institute | Modulation of γδ T cells |
| JP6890546B2 (ja) | 2015-04-02 | 2021-06-18 | メモリアル スローン ケタリング キャンサー センター | Ｔｎｆｒｓｆ１４／ｈｖｅｍタンパク質およびその使用の方法 |
| JP2018521959A (ja) | 2015-04-29 | 2018-08-09 | サンフォード−バーナム メディカル リサーチ インスティテュート | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション |
| KR20240110000A (ko) | 2015-06-30 | 2024-07-12 | 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 | Btla 융합 단백질 작용제 및 이의 용도 |
| WO2017144668A1 (en) | 2016-02-26 | 2017-08-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity for btla and uses thereof |
| WO2017211321A1 (zh) | 2016-06-08 | 2017-12-14 | 上海交通大学医学院 | 增强激动型抗体活性的抗体重链恒定区序列 |
| TWI847958B (zh) | 2016-07-05 | 2024-07-11 | 英屬開曼群島商北極星藥業集團股份有限公司 | 用精胺酸耗盡劑進行之組合癌症免疫療法 |
| US12447213B2 (en) | 2016-10-07 | 2025-10-21 | The Broad Institute, Inc. | Modulation of novel immune checkpoint targets |
| MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| US20200140547A1 (en) | 2017-05-26 | 2020-05-07 | The Johns Hopkins University | Multifunctional antibody-ligand traps to modulate immune tolerance |
| WO2019080898A1 (en) | 2017-10-27 | 2019-05-02 | Shanghai Yao Yuan Biotechnology Co., Ltd. | COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE RESPONSE BY ACTIVATION OF PROTEIN KINASE ALPHA 1 |
| EP3707163A4 (en) | 2017-11-09 | 2021-08-18 | The General Hospital Corporation | POLYPEPTIDES ANTAGONISTS OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY |
| PE20210342A1 (es) | 2018-05-25 | 2021-02-23 | Alector Llc | Anticuerpos anti-sirpa y metodos de utilizacion de los mismos |
| WO2019245817A1 (en) | 2018-06-19 | 2019-12-26 | Armo Biosciences, Inc. | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
| US12060422B2 (en) | 2018-06-29 | 2024-08-13 | Alector Llc | Anti-SIRP-Beta1 antibodies and methods of use thereof |
| US20210340268A1 (en) | 2018-08-20 | 2021-11-04 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
| WO2020053833A1 (en) | 2018-09-14 | 2020-03-19 | Université de Lausanne | Methods for modulating regulatory t cells and inhibiting tumor growth |
| WO2020102739A1 (en) | 2018-11-15 | 2020-05-22 | The General Hospital Corporation | Agonistic tumor necrosis factor receptor superfamily polypeptides |
-
2016
- 2016-06-29 KR KR1020247017225A patent/KR20240110000A/ko active Pending
- 2016-06-29 KR KR1020187002960A patent/KR102669985B1/ko active Active
- 2016-06-29 WO PCT/US2016/040108 patent/WO2017004213A1/en not_active Ceased
- 2016-06-29 AU AU2016286108A patent/AU2016286108B2/en active Active
- 2016-06-29 US US15/737,259 patent/US10961297B2/en active Active
- 2016-06-29 BR BR112017028316-6A patent/BR112017028316A2/en active Search and Examination
- 2016-06-29 JP JP2017568205A patent/JP7116285B2/ja active Active
- 2016-06-29 MX MX2018000073A patent/MX2018000073A/es unknown
- 2016-06-29 IL IL256383A patent/IL256383B2/en unknown
- 2016-06-29 CA CA2990885A patent/CA2990885A1/en active Pending
- 2016-06-29 EP EP16818691.4A patent/EP3317297A4/en active Pending
- 2016-06-29 EA EA201890171A patent/EA201890171A1/ru unknown
- 2016-06-29 CN CN202210348320.0A patent/CN114853903A/zh active Pending
- 2016-06-29 SG SG10201913567QA patent/SG10201913567QA/en unknown
- 2016-06-29 IL IL297395A patent/IL297395B2/en unknown
- 2016-06-29 CN CN201680049768.5A patent/CN108026159B9/zh active Active
-
2021
- 2021-03-01 US US17/188,912 patent/US11939367B2/en active Active
- 2021-05-17 JP JP2021083133A patent/JP2021113240A/ja active Pending
- 2021-06-08 AU AU2021203768A patent/AU2021203768B2/en active Active
-
2022
- 2022-07-20 JP JP2022115473A patent/JP7559013B2/ja active Active
-
2023
- 2023-04-14 AU AU2023202302A patent/AU2023202302A1/en not_active Abandoned
- 2023-12-13 JP JP2023210069A patent/JP2024019529A/ja active Pending
-
2024
- 2024-02-15 US US18/442,988 patent/US20240247047A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7746499B2 (ja) | Ｃｌｅｃ９ａ結合物質およびその使用 | |
| JP2018521999A5 (enExample) | ||
| JP7476467B2 (ja) | 標的化キメラタンパク質及びその使用 | |
| CN111328286B (zh) | Pd-1和pd-l1结合剂 | |
| CN110114368B (zh) | 靶向突变干扰素-γ及其用途 | |
| US20240247047A1 (en) | BTLA Fusion Protein Agonists and Uses Thereof | |
| JP2017533207A5 (enExample) | ||
| CN114805573A (zh) | 抗tim3单克隆抗体和嵌合抗原受体 | |
| US20250320302A1 (en) | Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection | |
| JP2025181864A (ja) | Ｃｌｅｃ９ａ結合物質およびその使用 | |
| HK40074138A (en) | Anti-tim3 monoclonal antibodies and chimeric antigen receptors | |
| HRP20210383T1 (hr) | Kombinirana terapija za rak | |
| Branschädel | Analysis of molecular components essential for the formation of signaling-competent TNF-TNFR complexes |